Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,426Revenue $M747Net Margin (%)13.0Altman Z-Score16.6
Enterprise Value $M2,271EPS $1.3Operating Margin %21.5Piotroski F-Score6
P/E(ttm)27.4Beneish M-Score-2.8Pre-tax Margin (%)21.4Higher ROA y-yN
Price/Book3.210-y EBITDA Growth Rate %--Quick Ratio4.6Cash flow > EarningsY
Price/Sales3.35-y EBITDA Growth Rate %13.5Current Ratio5.2Lower Leverage y-yY
Price/Free Cash Flow17.5y-y EBITDA Growth Rate %-21.6ROA % (ttm)12.2Higher Current Ratio y-yY
Dividend Yield %--PEG2.1ROE % (ttm)13.9Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M71.3ROIC % (ttm)18.3Gross Margin Increase y-yN

Gurus Latest Trades with MYGN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
MYGNKen Fisher 2015-09-30 Add$30.94 - $41.39
($35.43)
$ 34.63-2%Add 1.96%89,775
MYGNJoel Greenblatt 2015-03-31 Sold Out -0.16%$32.63 - $39.49
($35.79)
$ 34.63-3%Sold Out0
MYGNMario Gabelli 2015-03-31 Buy $32.63 - $39.49
($35.79)
$ 34.63-3%New holding25,000
MYGNKen Fisher 2015-03-31 Reduce$32.63 - $39.49
($35.79)
$ 34.63-3%Reduce -0.32%88,050
MYGNJoel Greenblatt 2014-12-31 Reduce-0.11%$32.01 - $39.49
($35.44)
$ 34.63-2%Reduce -34.58%568,865
MYGNKen Fisher 2014-12-31 Buy 0.01%$32.01 - $39.48
($35.39)
$ 34.63-2%New holding88,333
MYGNJoel Greenblatt 2014-09-30 Reduce-0.12%$35.44 - $40.41
($37.28)
$ 34.63-7%Reduce -22.18%869,531
MYGNFirst Eagle Investment 2014-06-30 Sold Out -0.03%$33.1 - $42.21
($37.18)
$ 34.63-7%Sold Out0
MYGNThird Avenue Management 2014-03-31 Sold Out -0.13%$20.79 - $38.17
($30.6)
$ 34.6313%Sold Out0
MYGNFirst Eagle Investment 2014-03-31 Buy 0.03%$20.79 - $38.17
($30.6)
$ 34.6313%New holding284,826
MYGNRonald Muhlenkamp 2013-12-31 Sold Out -2.3%$20.79 - $30.65
($25.36)
$ 34.6337%Sold Out0
MYGNJoel Greenblatt 2013-12-31 Add0.18%$20.79 - $30.65
($25.36)
$ 34.6337%Add 36.27%1,316,314
MYGNThird Avenue Management 2013-12-31 Buy 0.13%$20.79 - $30.65
($25.36)
$ 34.6337%New holding328,314
MYGNJoel Greenblatt 2013-09-30 Add0.32%$24.396 - $31.8
($28.51)
$ 34.6321%Add 74.78%965,987
MYGNRonald Muhlenkamp 2013-06-30 Buy 2.7%$24.35 - $34.26
($28.98)
$ 34.6319%New holding481,900
MYGNRon Baron 2013-06-30 Sold Out -0.09%$24.35 - $34.26
($28.98)
$ 34.6319%Sold Out0
MYGNJoel Greenblatt 2013-03-31 Add0.24%$24.19 - $27.68
($25.95)
$ 34.6333%Add 62.99%489,388
MYGNRon Baron 2013-03-31 Buy 0.09%$24.19 - $27.68
($25.95)
$ 34.6333%New holding658,653
MYGNJoel Greenblatt 2012-03-31 Add0.22%$20.36 - $25.64
($21.82)
$ 34.6359%Add 40.27%363,079
MYGNJoel Greenblatt 2011-12-31 Add0.11%$18.25 - $21.76
($20.37)
$ 34.6370%Add 21.40%258,844
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

MYGN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


MYGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
GILBERT WALTER PHDDirector 2015-12-11Sell5,000$42.23-18view
Phanstiel S. LouiseDirector 2015-12-08Sell5,000$44-21.3view
DREISMANN HEINRICHDirector 2015-11-05Sell60,000$44.44-22.07view
MARSH RICHARD ME.V.P., General Counsel 2015-11-04Sell35,000$44.5-22.18view
King Gary A.Exec. VP International Ops 2015-10-28Sell10,000$42.82-19.13view
LANCHBURY JERRY SChief Scientific Officer 2015-10-28Sell50,962$41.86-17.27view
LANCHBURY JERRY SChief Scientific Officer 2015-10-27Sell24,767$41.8-17.15view
LANCHBURY JERRY SChief Scientific Officer 2015-09-17Sell60,270$39.89-13.19view
MARSH RICHARD ME.V.P., General Counsel 2015-09-16Sell35,000$41.25-16.05view
King Gary A.Exec. VP International Ops 2015-09-14Sell14,562$39.41-12.13view

Quarterly/Annual Reports about MYGN:

News about MYGN:

Articles On GuruFocus.com
Chuck Royce Reduces Several Positions in 4th Quarter Feb 05 2016 
Chuck Royce Comments on Myriad Genetics Oct 08 2014 
Chuck Royce’s Royce Premier Fund Second Quarter 2014 Manager Commentary Oct 08 2014 
Why I Bought Myriad Genetics (MYGN) Apr 28 2014 
Scott Black, Delphi Management Recommends Stocks Nov 19 2013 
Surfing for Billionaire Bargains Sep 22 2013 
Baron Funds Comments on Myriad Genetics Inc. Jun 06 2013 
RS Investments' Value Fund First Quarter 2012 Mutual Fund Commentary Apr 17 2012 
Chuck Royce Buys Hawkins Inc., Myriad Genetics, and Fairchild Semiconductor Jul 07 2011 
Myriad Genetics Inc. Reports Operating Results (10-Q) May 05 2010 

More From Other Websites
MYRIAD GENETICS INC Financials Feb 06 2016
Myriad Genetics, Inc. Earnings Analysis: Q2, 2016 By the Numbers Feb 05 2016
Myriad Genetics Tops Q2 Earnings; myRisk Conversion Over Feb 03 2016
MYRIAD GENETICS INC Files SEC form 10-Q, Quarterly Report Feb 03 2016
Edited Transcript of MYGN earnings conference call or presentation 2-Feb-16 9:30pm GMT Feb 02 2016
[$$] Myriad Genetics Reports Higher Earnings and Boosts Guidance Feb 02 2016
Myriad tops Street 2Q forecasts Feb 02 2016
Myriad tops Street 2Q forecasts Feb 02 2016
MYRIAD GENETICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Feb 02 2016
Myriad Genetics Reports Fiscal Second-Quarter 2016 Financial Results Feb 02 2016
Q2 2016 Myriad Genetics Inc Earnings Release - After Market Close Feb 02 2016
Will Myriad Genetics Q2 Earnings (MYGN) Surprise Investors? Jan 27 2016
Myriad to Announce Fiscal Second-Quarter 2016 Financial Results on February 2 Jan 21 2016
Myriad to Announce Fiscal Second-Quarter 2016 Financial Results on February 2 Jan 21 2016
Myriad Genetics: Urologic Cancer Assays Positive in Trials Jan 08 2016
Coverage initiated on Myriad Genetics by Deutsche Bank Jan 07 2016
Myriad Genetics, Thermo Fisher Two Top Life Science & Diagnostic Picks At Deutsche Bank Jan 07 2016
Myriad Advances Prostate and Renal Cancer Molecular Diagnostic Tests at the 2016 ASCO Genitourinary... Jan 07 2016
Myriad Advances Prostate and Renal Cancer Molecular Diagnostic Tests at the 2016 ASCO Genitourinary... Jan 07 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

Antoniy
ReplyAntoniy - 2 years ago
hs
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK